Immune activation suppresses initiation of lytic Epstein-Barr virus infection.

Laboratory for Experimental Infectious Diseases and Cancer Research of the Division of Infectious Diseases, University Children's Hospital of Zurich, 8032 Zurich, Switzerland.
Cellular Microbiology (Impact Factor: 4.82). 09/2007; 9(8):2055-69. DOI: 10.1111/j.1462-5822.2007.00937.x
Source: PubMed

ABSTRACT Primary infection with Epstein-Barr virus (EBV) is asymptomatic in children with immature immune systems but may manifest as infectious mononucleosis, a vigorous immune activation, in adolescents or adults with mature immune systems. Infectious mononucleosis and chronic immune activation are linked to increased risk for EBV-associated lymphoma. Here we show that EBV initiates progressive lytic infection by expression of BZLF-1 and the late lytic genes gp85 and gp350/220 in cord blood mononuclear cells (CBMC) but not in peripheral blood mononuclear cells (PBMC) from EBV-naive adults after EBV infection ex vivo. Lower levels of proinflammatory cytokines in CBMC, used to model a state of minimal immune activation and immature immunity, than in PBMC were associated with lytic EBV infection. Triggering the innate immunity specifically via Toll-like receptor-9 of B cells substantially suppressed BZLF-1 mRNA expression in acute EBV infection ex vivo and in anti-IgG-stimulated chronically latently EBV-infected Akata Burkitt lymphoma cells. This was mediated in part by IL-12 and IFN-gamma. These results identify immune activation as critical factor for the suppression of initiation of lytic EBV infection. We hypothesize that immune activation contributes to EBV-associated lymphomagenesis by suppressing lytic EBV and in turn promotes latent EBV with transformation potential.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to understand and possibly treat B-cell malignancies associated with latent gamma-herpesvirus infection, it is vital to understand the factors that control the balance between the two transcriptional states of gamma-herpesviruses: latency and lytic replication. We used murine gamma-herpesvirus (MHV)-68 as a model system to investigate how engagement of endosomal Toll-like receptors (TLRs) impacts on reactivation from latency in vitro and on establishment of latent infection in vivo. We found that treatment with TLR7 ligand R848 or TLR9 ligand CpG ODN suppresses reactivation of MHV-68 in vitro. These suppressive effects correlated with the ability to activate cellular transcription factor NFκB. Downregulation of TLR9 by RNA interference in vitro led to a reduction of nuclear levels of NFκB p65 and consequently to an increase of spontaneous reactivation in MHV-68 latently infected cells, indicating that the TLR9 pathway contributes to limiting spontaneous reactivation events. In vivo, sustained stimulation of TLR7 by repeated R848 treatment led to an increased frequency of infected splenocytes compared to mock-treated control. Frequencies of infected splenic B-cells in tlr7(-/-) or tlr9(-/-) mice after establishment of latency did not differ from their wild-type counterpart. Nevertheless, MHV-68-infected B-cells from tlr9(-/-) mice showed a higher frequency of reactivation compared to B-cells from wild-type or tlr7(-/-) mice in ex vivo reactivation assays. Thus, we show a suppressive effect of TLR7 or TLR9 triggering on MHV-68 reactivation that correlates with NFκB activation and that the mere presence of functional TLR9 signaling pathway contributes to dampen lytic gamma-herpesvirus reactivation in infected cells.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epstein-Barr virus (EBV) is a ubiquitous human γ-herpes virus which establishes a life-long asymptomatic infection in immunocompetent hosts. In human immunodeficiency virus type 1 (HIV-1) infected patients, the impaired immunosurveillance against EBV may favor the development of EBV-related diseases, ranging from lymphoproliferative disorders to B cell non-Hodgkin's lymphomas (NHL). Antiretroviral therapy (ART) has significantly modified the natural course of HIV-1 infection, resulting in decreased HIV-1 plasmaviremia, increased CD4 lymphocytes, and decreased opportunistic infections, indicating a restoration of immune functions. However, the impact of ART appears to be less favorable on EBV-related malignancies than on other AIDS-defining tumors, such as Kaposi's sarcoma, and NHL remains the most common cancer during the ART era. EBV-driven tumors are associated with selective expression of latent oncogenic proteins, but uncontrolled lytic cycle with virus replication and/or reactivation may favor cell transformation, at least in the early phases. Several host's factors may promote EBV reactivation and replication; besides immunodepression, inflammation/chronic immune stimulation may play an important role. Microbial pathogen-associated molecular patterns and endogenous damage-associated molecular patterns, through Toll-like receptors, activate the immune system and may promote EBV reactivation and/or polyclonal expansion of EBV-infected cells. A body of evidence suggests that chronic immune stimulation is a hallmark of HIV-1 pathogenesis and may persist even in ART-treated patients. This review focuses on lymphomagenesis driven by EBV both in the context of the natural history of HIV-1 infection and in ART-treated patients. Understanding the mechanisms involved in the expansion of EBV-infected cells is a premise for the identification of prognostic markers of EBV-associated malignancies.
    Frontiers in Microbiology 10/2013; 4:311. DOI:10.3389/fmicb.2013.00311 · 3.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epstein-Barr virus (EBV) infects more than 90% of the human population within the first two decades of life and establishes reversible latent infection in B cells. Which stimuli leads to switching from latent to lytic EBV infection in vivo are still elusive. Group A Streptococci (GAS) are a common cause of bacterial pharyngotonsillitis in children and adolescents and colonize tonsil and pharynx of up to 20% of healthy children. Thus, concomitant presence of EBV and GAS in the same individual is frequent. Here, we show that EBV carriers who are colonized with GAS shed EBV particles in higher numbers in their saliva compared to EBV carriers not colonized with GAS. mRNA levels of the master lytic regulatory EBV gene BZLF1 were more frequently detected in tonsils from EBV-carriers colonized with GAS than from not colonized. Heat-killed GAS, potentially mimicking GAS colonization, elicited lytic EBV in latently infected lymphoblastoid cell lines (LCLs) partially via TLR2 triggering, as did purified GAS peptidoglycan. Thus, EBV may benefit from colonizing GAS that by increasing the EBV load in saliva may contribute to enhancing the viral spread to other hosts.
    The Journal of Infectious Diseases 08/2013; DOI:10.1093/infdis/jit428 · 5.78 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014